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many curriculums, both in medical schools and in
postgraduate training. Evidence based textbooks have
been written for the Brazilian context.7 Additionally,
post-residency training is now offered in more than
300 masters or doctoral programmes in health related
fields throughout the country, representing a major
resource for capacity building and research.
To align academic medicine more directly with the
SUS, the Ministry of Health has instituted regional
centres for training within the new primary care
model8; redirected residency slots to family medicine;
expanded in-house training for core personnel of the
health system at local, state, and national levels; and
funded programmes to help medical schools to make
their curriculums more relevant to practice within the
SUS. National funding for research and prizes for aca-
demic excellence are increasingly awarded to work that
will help solve the problems faced by the SUS.
The national health service now depends on
academic support to develop and identify innovations
that should be translated into effective health actions,9
to crystallise the state of the art into clinical and public
health guidelines,10 to monitor the provision of care,11
and to evaluate health system initiatives.12 Academic
input also buffers the system against undue alterations
resulting from shifts in the prevailing political winds,
parties, and players.
Yet improving population health in Brazil will
demand even greater academic participation. Can aca-
demic medicine meet these challenges? Only through
change. Our experience is that change from within the
academic structure is painfully slow in coming, making
external incentives from the government and other key
institutions vitally important.
In this regard, the pharmaceutical and technology
industries provide incentives through funding
research, medical gatherings, and other forms of
continuing medical education. Their frequently mas-
sive commercial expenditures, however, often over-
whelm more rational approaches to healthcare
provision. In countries like Brazil with still limited gov-
ernmental action and expertise in technology assess-
ment, it is vital that academic medicine continues to
question the ground rules for its partnerships with
industry while strengthening its partnerships with the
national health system.
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Home blood glucose monitoring in type 2 diabetes
Regular monitoring is necessary only in some situations
Diabetes UK, the leading charity for people withdiabetes in the United Kingdom, issued thefollowing position statement in July 2003.1
“People with diabetes should have access to home
blood glucose monitoring based on individual clinical
need, informed consent and not on ability to pay.
Home monitoring is essential in the context of
diabetes education for self-management in order to
enable the person to make appropriate treatment or
lifestyle choices.” The first part of this statement is not
contentious, and most people would probably agree
that people with type 1 or type 2 diabetes treated with
insulin should regularly monitor blood glucose, not
only to guide insulin doses but also to detect and avoid
hypoglycaemia. However, is home blood glucose
monitoring necessary for people with type 2 diabetes
treated with oral hypoglycaemic agents and dietary
modification?
Home blood glucose monitoring is a big business.
The main profit for the manufacturing industry comes
from the blood glucose testing strips. Some £90m was
spent on testing strips in the United Kingdom in 2001,
40% more than was spent on oral hypoglycaemic
agents.2 New types of meters are usually not subject to
the same rigorous evaluation of cost effectiveness,
compared with existing models, as new pharmaceutical
agents are.
Practice varies among healthcare professionals
with regard to the recommended frequency of home
blood glucose monitoring, but proponents argue that
it empowers people with type 2 diabetes. For example,
people who monitor themselves may observe the effect
that eating and exercise have on their blood glucose
concentrations, and this information may help
promote alterations in diet and physical activity.3 Yet
some evidence exists that home blood glucose
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monitoring has an adverse effect on quality of life, with
higher levels of distress, worry, and depressive
symptoms, particularly if patients test more than once
a day.4
The impact of home blood glucose monitoring in
type 2 diabetes was considered in an NHS health tech-
nology assessment in 2000.5 Many studies identified
were poorly designed, lacked statistical power, and
were difficult to compare as the groups of patients
were different and because glucose monitoring may
have been just one part of a multifactorial intervention
programme. A meta-analysis was performed on data
from four studies in people with type 2 diabetes that
compared home monitoring of blood glucose or urine
glucose with no monitoring. Glycaemic control (as
assessed by glycated haemoglobin) between the two
groups was found to be no different. No difference was
found in glycated haemoglobin in three studies that
compared people who monitored blood glucose with
those who monitored urine glucose. Moreover,
individual studies did not provide evidence of other
potential benefits such as reduction in episodes of
hypoglycaemia or improvements in quality of life.
The guidelines from the Scottish Intercollegiate
Guidelines Network offered no recommendations
about home blood glucose monitoring in type 2 diabe-
tes, concluding that there were no studies that had
adequately assessed the benefits of glucose monitoring
in glycaemic control.6 By contrast, the National
Institute for Clinical Excellence supported the use of
home blood glucose monitoring in type 2 diabetes,7
although it indicated that this should be taught only as
part of “integrated self care” and “if the purpose . . . is
agreed with the patient.” More recently, a multidiscipli-
nary group of healthcare professionals published con-
sensus advice on home blood glucose monitoring.8
The group agreed that such monitoring was not
required routinely in type 2 diabetes but suggested that
people should monitor in special circumstances. These
included measuring blood glucose once a day during
intercurrent illness, when oral hypoglycaemic treat-
ment is changed, if systemic glucocorticoids are
prescribed, and if post-prandial hyperglycaemia
occurs. Home blood glucose monitoring was also sug-
gested for patients taking sulphonylureas because of
the risk of hypoglycaemia. None of these recommen-
dations was supported by evidence from randomised
trials.
If the scientific evidence supporting the role of
home blood glucose monitoring in type 2 diabetes was
subject to the same critical evaluation that is applied to
new pharmaceutical agents, then it would perhaps not
have been approved for use by patients. For people
with diabetes controlled with diet and tablets,
glycaemic control could be monitored more cost effec-
tively by using glycated haemoglobin alone, measured
at three to four monthly intervals. Common sense dic-
tates that in some situations home blood glucose
monitoring is desirable, such as when systemic steroids
are prescribed or during pregnancy. However, we need
to move away from consensus recommendations and
perform large randomised trials examining the role of
home blood glucose monitoring in type 2 diabetes. In
addition, new models of blood glucose meters need to
be subjected to the same rigorous evaluation of cost
effectiveness as is applied to pharmaceutical agents.
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Aspartame and its effects on health
The sweetener has been demonised unfairly in sections of the press and several
websites
The European population of 375 millionconsumes about 2000 tonnes annually ofaspartame (NutraSweet, Canderel) an artificial
sweetener, which contains two amino acids—aspartic
acid and phenylalanine.1 It is 180-200 times sweeter
than sucrose, and almost half a million extra tonnes of
sugar would therefore be needed to generate the same
sweetness. Was the world screaming for all this
sweetness, and what has it done to us? Anyone
searching the web on aspartame, launched in 1981 by
Monsanto, the manufacturer of NutraSweet, will find a
vast catalogue of frightening personal accounts attrib-
uting multiple health disasters to exposure to
aspartame.1 Although no orchestrated public outcry
about aspartame has taken place, much sensationalist
journalism has been published mostly on websites (for
example, www.holisticmed.com/aspartame/). In con-
trast, aspartame marketing implies that it embodies a
healthy way of life and avoids obesity. Are these claims
of hazards and benefits supported by evidence?
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